Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 4/20 | 0.52 |
| ▸ | CACNA1H | O95180 | 4/20 | 0.52 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | PRCP | P42785 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 10/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 10/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7544584 | 0.99 | CACNA1G (0.51) | CACNA1GCACNA1HGRIN2DGRIN3BCYP2B6 | |
| Hydrochloric Acid SCHEMBL7492871 | 0.95 | CACNA1G (0.50) | CACNA1GCACNA1HGRIN2DGRIN3BCYP2B6 | |
| SCHEMBL7489124 | 0.92 | CACNA1G (0.47) | CACNA1GCACNA1HGRIN2DGRIN3BCYP2B6 | |
| Hydrochloric Acid SCHEMBL7490044 | 0.91 | OPRM1 (0.47) | CACNA1GCACNA1HGRIN2DGRIN3BCYP2B6 | |
| SCHEMBL7489304 | 0.88 | CACNA1G (0.51) | CACNA1GCACNA1HGRIN2DGRIN3BCYP2B6 | |
| SCHEMBL6834480 | 0.85 | CACNA1G (0.52) | CACNA1GCACNA1HGRIN2DGRIN3BCYP2B6 | |
| SCHEMBL7491980 | 0.84 | CACNA1G (0.46) | CACNA1GCACNA1HGRIN2DGRIN3BCYP2B6 | |
| SCHEMBL7493212 | 0.83 | CYP2D6 (0.49) | CACNA1GCACNA1HGRIN2DGRIN3BCYP2B6 | |
| SCHEMBL7495757 | 0.83 | OPRL1 (0.48) | CACNA1GCACNA1HGRIN2DGRIN3BCYP2B6 | |
| SCHEMBL6840940 | 0.82 | CACNA1G (0.47) | CACNA1GCACNA1HKCNH2OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6423725-B1 | ANALGESICS | PFIZER INC | 2002-07-23 | — | — | US | claimed |
| EP-1049689-B1 | 4-(2-KETO-1-BENZIMIDAZOLINYL)PIPERIDINE COMPOUNDS AS ORL1-RECEPTOR AGONISTS | PFIZER (US) | 2002-06-26 | — | — | EP | claimed |
| EP-1049689-A1 | 4-(2-KETO-1-BENZIMIDAZOLINYL)PIPERIDINE COMPOUNDS AS ORL1-RECEPTOR AGONISTS | PFIZER INC. (US) | 2000-11-08 | — | — | EP | claimed |
| WO-1999036421-A1 | 4-(2-KETO-1-BENZIMIDAZOLINYL)PIPERIDINE COMPOUNDS AS ORL1-RECEPTOR AGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 1999-07-22 | — | — | WO | claimed |
| US-20040067950-A1 | High affinity ligands for nociceptin receptor ORL-1 | SCHERING-PLOUGH CORPORATION | 2004-04-08 | — | — | US | disclosed |
| US-6423725-B1 | ANALGESICS | PFIZER INC | 2002-07-23 | — | — | US | disclosed |
| EP-1049689-B1 | 4-(2-KETO-1-BENZIMIDAZOLINYL)PIPERIDINE COMPOUNDS AS ORL1-RECEPTOR AGONISTS | PFIZER (US) | 2002-06-26 | — | — | EP | disclosed |
| EP-1200087-A1 | NOCICEPTIN RECEPTOR ORL-1 AGONISTS FOR USE IN TREATING COUGH | SCHERING CORPORATION (US) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001007050-A1 | NOCICEPTIN RECEPTOR ORL-1 AGONISTS FOR USE IN TREATING COUGH | SCHERING CORPORATION (US) | 2001-02-01 | — | — | WO | disclosed |
| EP-1049689-A1 | 4-(2-KETO-1-BENZIMIDAZOLINYL)PIPERIDINE COMPOUNDS AS ORL1-RECEPTOR AGONISTS | PFIZER INC. (US) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999036421-A1 | 4-(2-KETO-1-BENZIMIDAZOLINYL)PIPERIDINE COMPOUNDS AS ORL1-RECEPTOR AGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 1999-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067950-A1 | High affinity ligands for nociceptin receptor ORL-1 | OPRL1, OPRD1, OGFRL1 | CACNA1G 455/4885CACNA1H 398/4885GRIN2D 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.